Verrica Pharmaceuticals (VRCA) closed at $3.56 on November 13, 2026, down 4.3% from the previous close, on volume of 17,826 shares (30-day average 57,618).
Data as of November 13, 2026.
13-Nov-2026
Verrica Pharmaceuticals Earnings Call Shows Growth and Pipeline Progress
TipRanks (Sun, 15-Nov 12:04 AM ET)
TipRanks (Fri, 13-Nov 10:00 AM ET)
TipRanks (Fri, 13-Nov 9:10 AM ET)
Verrica Pharmaceuticals Non-GAAP EPS of -$0.49 in-line, revenue of $6.9M beats by $0.7M
Seeking Alpha News (Thu, 12-Nov 4:52 PM ET)
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 12-Nov 4:16 PM ET)
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
Globe Newswire (Tue, 10-Nov 8:00 AM ET)
Globe Newswire (Thu, 5-Nov 8:00 AM ET)
Globe Newswire (Thu, 22-Oct 8:00 AM ET)
Verrica Pharmaceuticals to Present New YCANTH Data Analysis at Two Upcoming Dermatology Conferences
Globe Newswire (Wed, 30-Sep 8:00 AM ET)
Verrica Pharmaceuticals to Present YCANTH and VP-315 Data at Two Upcoming Dermatology Conferences
Globe Newswire (Thu, 10-Sep 8:05 AM ET)
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Verrica Pharmaceuticals trades on the NASDAQ stock market under the symbol VRCA.
As of November 13, 2026, VRCA stock price declined to $3.56 with 17,826 million shares trading.
VRCA has a beta of 3.48, meaning it tends to be more sensitive to market movements. VRCA has a correlation of 0.16 to the broad based SPY ETF.
VRCA has a market cap of $61.16 million. This is considered a Micro Cap stock.
Last quarter Verrica Pharmaceuticals reported $7 million in Revenue and -$.49 earnings per share. This beat revenue expectation by $723,656 and met earnings estimates .
In the last 3 years, VRCA traded as high as $114.10 and as low as $3.08.
The top ETF exchange traded funds that VRCA belongs to (by Net Assets): VTI, VXF, IWC.
VRCA has underperformed the market in the last year with a return of -8.0%, while the SPY ETF gained +13.4%. In the last 3 month period, VRCA fell short of the market, returning -26.7%, while SPY returned -2.8%. However, in the most recent 2 weeks VRCA has outperformed the stock market by returning +6.3%, while SPY returned -0.2%.
VRCA support price is $3.44 and resistance is $4.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRCA shares will trade within this expected range on the day.
